VIR-5818 is an investigational dual-masked T-cell engager targeting HER2-expressing solid tumors. Early Phase 1 data showed dose-dependent tumor shrinkage in heavily pretreated participants, and the program continues in monotherapy and pembrolizumab-combination cohorts. It has not received marketing approval.
Vir Biotechnology reported Q4 EPS of ($0.31), beating estimates by $0.23, with revenue of $64.07 million. The company announced a global strategic collaboration with Astellas for VIR-5500 and reported $781.6 million in cash and investments.
Vir Biotechnology announced a global strategic collaboration with Astellas for VIR-5500, a PSMA-targeted dual-masked T-cell engager for prostate cancer, and reported $781.6 million in cash and investments as of December 31, 2025.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05356741 |
To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers |
RECRUITING | PHASE1/PHASE2 |
